MICHAEL BLAIN: Open Payments
NPI 1801076146 · ELDORADO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$905 in 46 payments from 16 companies in 2025. Trend: 2023 $843 · 2024 $785 · 2025 $905
Food & beverage: $905
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $166 |
| Neurocrine BioSciences, Inc. | 5 | $105 |
| Axsome Therapeutics, Inc. | 5 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| E.R. Squibb & Sons, L.L.C. | 5 | $86 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| Janssen Pharmaceuticals, Inc | 3 | $64 |
| Merck Sharp & Dohme LLC | 3 | $58 |
| Braeburn Inc. | 2 | $45 |
| Novo Nordisk Inc | 1 | $24 |
Products named: ARISTADA, INGREZZA, Auvelity, COBENFY, REXULTI, FANAPT, SPRAVATO, BRIXADI.
Industry payments across IL — which companies pay providers there.
